Therapies Can Have Broader Utility than Screens Identify
One of the challenges of targeted therapies is to figure out who will benefit from them. In data presented at the San Antonio Breast Cancer Symposium, clinicians identified a group of breast tumors that did not overexpress HER2, but nevertheless were sensitive to HER2 inhibitors
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST